Effect of High-Density Lipoprotein Associated Cyclosporine on Hepatic Metabolism and Renal Function

PDA Journal of Pharmaceutical Science and Technology

Volumn 57, Issue 5, 2003, Pages 341-350

  Kim, Taekrho ^a   Callahan, Shellie M ^a   Wasan, Kishor M ^b   Brunner, Lane J ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2ALPHA HYDROXYTESTOSTERONE; 6BETA HYDROXYTESTOSTERONE; BIOLOGICAL MARKER; CREATININE; CREMOPHOR; CYCLOSPORIN A; CYTOCHROME P450 2C11; CYTOCHROME P450 3A; HIGH DENSITY LIPOPROTEIN; IMMUNOSUPPRESSIVE AGENT; SODIUM CHLORIDE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG EFFECT; DRUG SOLUTION; ENZYME ACTIVITY; ENZYME REPRESSION; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LIVER METABOLISM; MALE; NONHUMAN; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; CHOLESTEROL, HDL; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG COMBINATIONS; HUMANS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0345687208     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. S. L. Schreiber, G. R. Crabtree, The mechanism of action of cyclosporin A and FK506. Immunol Today 13, 136 (1992).
2. R. Palacios, Concanavalin a triggers t-lymphocytes by directly interacting with their receptors for activation. J. Immunol. 128, 337 (1982).
3. H. S. Lillehoj, T. R. Malek, E. M. Shevach, Differential effect of cyclosporin a on the expression of T and B lymphocyte activation antigens. J. Immunol. 133, 244 (1984).
4. J. M. Hows, S. Palmer, S. Want, C. Dearden, E. C. Gordon-Smith, Serum levels of cyclosporine A and nephrotocixity in bone marrow tranplant patients. Lancet, 2, 145 (1981).
5. G. B. Klintmalm, S. Iwatsuki, T. E. Starzl, Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1, 470 (1981).
6. M. D. Schulman, S. L. Acton, D. L. Valentino, B. H. Arison, Purification and identification of dTDP-oleandrose, the precursor of the oleandrose units of the avermectins. J. Biol. Chem. 265, 16965 (1990).
7. K. Atkinson, J. C. Biggs, J. Hayes, M. Ralston, A. J. Dodds, Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: Three distinct syndromes. Br. J. Haematol. 54, 59 (1983).
8. B. D. Myers, et al., The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 33, 590 (1988).
9. G. C. Yee, M. S. Kennedy, R. Storb, E. D. Thomas, Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in marrow transplant patients. Blood 64, 1277 (1984).
10. K. M. Wasan, M. Kwong, Blood and plasma lipoprotein distribution and gender differences in the plasma pharmacokinetics of lipid-associated annamycin. Pharmacology and Toxicology 80, 301 (1997).
11. D. R. Luke, L. J. Brunner, G. Lopez-Berestein, J. C. Yau, Pharmacokinetics of cyclosporine in bone marrow transplantation: Longitudinal characterization of drug in lipoprotein fractions. J. Pharm. Sci. 81, 208 (1992).
12. M. Lemaire, A. Fahr, G. Maurer, Pharmacokinetics of cyclosporine: inter- and intra-individual variation and metabolic pathways. Transplant Proc. 22, 1110 (1990).
13. A. Mbewu, P. N. Durrington, Lipoproteins involved in tissue repair. Atherosclerosis 85, 1 (1990).
14. J. C. Yau, L. J. Brunner, G. Lopez-Berestein, C. F. LeMaistre, D. R. Luke, Therapeutic drug monitoring of cyclosporine-lipoprotein levels. Pharmacotherapy 11, 291 (1991).
15. J. Lopez-Miranda, et al., Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 42, 678 (1993).
16. G. Ostermann, et al., The role of lipoproteins in the degradation of platelet-activating factor. Thromb. Res. Suppl. 44, 303 (1986).
17. A. Basile-Borgia, J. H. Abel, Lipoproteins and coagulation. Perfusion 12, 349 (1997).
18. J. A. K. Harmony, A. L. Aleson, In Biochemistry and Biology of Plasma Lipoproteins; Marcel Decker: New York, NY, 1981.
19. K. M. Wasan, S. M. Cassidy, Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharma. Sci. 87, 411 (1998).
20. R. W. Mahley, Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240, 622 (1988).
21. L. J. Brunner, et al., Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation. Ther. Drug Monit. 12, 134 (1990).
22. L. J. Brunner, K. Vadiei, D. R. Luke, Cyclosporine disposition in the hyperlipidemic rat model. Res. Commun. Chem. Pathol. Pharmacol. 59, 339 (1988).
23. P. C. De Groen, A. J. Aksamit, J. Rakela, G. S. Forbes, R. A. F. Krom, Central nervous system toxicity after liver transplantation: The role of cyclosporine and cholesterol. N. Engl. J. Med. 317, 861 (1987).
24. D. R. Nelson, et al., The P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1 (1996).
25. J. C. Kolars, et al., Cyclosporine metabolism by P450 IIIA in rat enterocytes: Another determination of oral bioavailability? Transplantation 53, 596 (1992).
26. L. J. Brunner, W. M. Bennett, D. R. Koop, Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner. Kidney Int. 54, 216 (1998).
27. L. J. Brunner, W. M. Bennett, D. R. Koop, Selective suppression of rat hepatic microsomal activity during chronic cyclosporine nephrotoxicity. J. Pharmcol. Exp. Ther. 277, 1710 (1996).
28. L. Pichard, et al., Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18, 595 (1990).
29. K. M. Wasan, et al., A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine. Pharm. Res. 16, 165 (1999).
30. W. Sattler, D. Mohr, R. Stocker, Rapid isolation of lipoproteins and assessment of their perioxdation by high-performance liquid chromatography postcolumn chemiluminescence. Methods Enzymol. 233, 469 (1994).
31. M. J. Coon, T. A. van der Hoeven, S. B. Dahl, D. A. Haugen, Two forms of liver microsomal cytochrome P-450, -450 LM2, P-450LM4 (Rabbit Liver). Meth. Enzymol. 52, 109 (1978).
32. O. H. Lowry, N. J. Rosebrough, A. L. Farr, R. J. Randall, Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265 (1951).
33. U. K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680 (1970).
34. G. G. Schnier, C. L. Laethem, D. R. Koop, Identification and induction of cytochromes P450, P450IIE1, and P450IA1 in rabbit bone marrow. J. Pharmacol. Exp. Ther. 251, 790 (1989).
35. M. P. Arlotto, J. M. Trant, R. W. Estabrook, Measurement of steroid hydroxylation reactions by high performance liquid chromatography as indicators of P450 identity and function. Methods Enzymol. 206, 454 (1991).
36. K. Nagata, F. J. Gonzlez, Y. Yamazoe, R. Kato, Purification and characterization of four catalytically active testosterone 6beta-hyroxylase P-450s from rat liver microsomes: comparison of a novel form with three structurally and functionally related forms. J. Biochem. 107, 718 (1990).
37. 5 and by microsomes: metabolite identification. J. Biol. Chem. 258, 11738 (1983).
38. P. C. De Groen, Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin. Proc. 63, 1012 (1988).
39. H. L. Verrill, R. E. Girgis, R. E. Easterling, B. S. Malhi, W. F. Mueller, Distribution of cyclosporine in blood of a renal-transplant recipient with type V hyperlipoproteinemia. Clin. Chem. 33, 423 (1987).
40. R. Kozyraki, et al., The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat. Med. 5, 656 (1999).
41. S. Imaoka, et al., Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem. Pharmacol. 51, 1041 (1996).